CLAIMS

1. Use of an oral pharmaceutical formulation comprising L-ornithine phenylacetate in the preparation of a medicament for treating or ameliorating hyperammonemia in a subject, wherein the medicament comprises a daily dose of 8 g to 12 g L-ornithine phenylacetate.

2. The use of Claim 1, wherein the medicament is for administration once a day.

3. The use of Claim 1, wherein the medicament comprises 4 g to 6 g L-ornithine phenylacetate for administration twice a day.

4. The use of Claim 3, wherein the 4 g to 6 g of L-ornithine phenylacetate is in a single unit dosage form.

5. The use of Claim 3, wherein the 4 g to 6 g of L-ornithine phenylacetate is in two or more unit dosage forms.

6. The use of Claim 5, wherein the 4 g to 6 g L-ornithine phenylacetate is in 4 to 6 unit dosage forms each comprising 1 g L-ornithine phenylacetate.

7. The use of any one of Claims 1 to 6, wherein said oral pharmaceutical formulation provides a plasma Cmax of phenylacetic acid from 10 μg/mL to 120 μg/mL.

8. The use of any one of Claims 1 to 7, wherein said oral pharmaceutical formulation provides a plasma Cmax of phenylacetylglutamine from 10 μg/mL to 80 μg/mL.

9. Use of an oral pharmaceutical formulation comprising L-ornithine phenylacetate in the preparation of a medicament for treating or ameliorating hyperammonemia in a subject, wherein the medicament comprises a daily dose of 8 g to 12 g L-ornithine phenylacetate and provides a plasma Cmax of phenylacetic acid ranging from 10 μg/mL to 150 μg/mL.

10. The use of Claim 9, wherein the plasma Cmax of phenylacetic acid is from 40 μg/mL to 120 μg/mL.

11. The use of Claim 9 or 10, wherein the plasma Cmax of phenylacetylglutamine is from 5 μg/mL to 100 μg/mL.

12. The use of Claim 11, wherein the plasma Cmax of phenylacetylglutamine is from 25 μg/mL to 50 μg/mL.

13. Use of an oral pharmaceutical formulation comprising L-ornithine phenylacetate in the preparation of a medicament for treating or ameliorating hyperammonemia in a subject, wherein the medicament comprises a daily dose of 8 g to 12 g L-ornithine phenylacetate and

provides a plasma $AUC_{0\text{-}t}$ or $AUC_{0\text{-}inf}$ of phenylacetic acid ranging from 100 hr*μg/mL to 1000 hr*μg/mL.

14. The use of Claim 13, wherein the plasma $AUC_{0\text{-}t}$ or $AUC_{0\text{-}inf}$ of phenylacetic acid is from 400 hr*μg/mL to 550 hr*μg/mL.

15. The use of Claim 13 or 14, wherein the plasma $AUC_{0\text{-}t}$ or $AUC_{0\text{-}inf}$ of phenylacetylglutamine is from 25 hr*μg/mL to 500 hr*μg/mL.

16. The use of Claim 15, wherein the plasma $AUC_{0\text{-}t}$ of phenylacetylglutamine is from 120 hr*μg/mL to 180 hr*μg/mL.

17. The use of Claim 15, wherein the plasma $AUC_{0\text{-}inf}$ of phenylacetylglutamine is from 150 hr*μg/mL to 200 hr*μg/mL.

18. The use of any one of Claims 1 to 17, wherein the subject has acute liver failure or chronic liver disease.

19. The use of Claim 18, wherein the subject has liver cirrhosis or liver decompensation, and wherein the liver cirrhosis has a classification of Child-Pugh class A, B or C.

20. The use of any one of Claims 1 to 17, wherein the subject has one or more conditions selected from the group consisting of hepatic encephalopathy, portal hypertension, and urea cycle disorder.

21. The use of any one of Claims 1 to 20, wherein the oral pharmaceutical formulation provides an immediate release of L-ornithine phenylacetate.

22. The use of any one of Claims 1 to 21, wherein said oral pharmaceutical formulation provides conversion of phenylacetate to phenylacetylglutamine of greater than 50% over 24 hours.

23. The use of Claim 22, wherein said oral pharmaceutical formulation provides conversion of phenylacetate to phenylacetylglutamine of greater than 80% over 24 hours.

24. The use of any one of Claims 1 to 23, wherein the medicament is for administration with food.